If you have been reading about size-exclusion HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
| Property | Value | Notes |
|---|---|---|
| Purity assessment | RP-HPLC, 214 nm | Wavelength affects relative peak areas |
| Identity confirmation | LC-MS/MS | Precursor and fragment ion masses compared |
| Common degradation | Deamidation, oxidation | Amide and methionine residues are main sites |
| Working solution storage | 2-8 °C, short term | Longer holding favours frozen aliquots |
| Adsorption risk | Higher below 1 mg/mL | Glass and plastic surfaces both affected |
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Luria–Nebraska Neuropsychological Battery A standardized test battery used to assess a wide range of cognitive and motor functions. Based on the work of Alexander Luria, it helps localize brain dysfunction.
Many people benefit from sleeping at a 30-degree elevation of the upper body or higher, as if in a recliner. Doing so helps prevent the gravitational collapse of the airway. Sleeping on a side as opposed to sleeping on the back ("supine position") is also recommended. Some studies have suggested that playing a wind instrument (such a didgeridoo, for example) may reduce snoring and apnea incidents. This may be especially true of double reed instruments.
== Side effects == Side effects of LGD-4033 may include headache and dry mouth. LGD-4033 has been found to dose-dependently decrease levels of total testosterone, free testosterone, follicle-stimulating hormone (FSH), sex hormone-binding globulin (SHBG), HDL cholesterol, and triglycerides, while not affecting levels of luteinizing hormone (LH), total cholesterol, LDL cholesterol, or prostate-specific antigen (PSA). Due to the decreased ratio of HDL cholesterol to LDL cholesterol, LGD-4033 could theoretically increase the risk of heart attack and stroke. Elevated liver enzymes, such as increased levels of aspartate aminotransferase (AST) or alanine aminotransferase (ALT), have not been reported with LGD-4033 in the few conducted clinical trials thus far. However, multiple case reports of hepatotoxicity with LGD-4033 in the setting of non-medical use have been published. LGD-4033 and other SARMs are largely uncharacterized in terms of their potential for masculinizing effects, for example in women. In addition, the effects and safety of high doses of LGD-4033 and other SARMs, which are often used in non-medical contexts, are unknown. Anecdotal reports of masculinization with black-market SARMs in women exist in online forums. The United States Food and Drug Administration (FDA) claims that "liver toxicity, adverse effects on blood lipid levels, and a potential to increase the risk of heart attack and stroke" are among the potential adverse health effects of SARMs including LGD-4033.
== Molecular mechanism == There are several inhibitors that can readily enter cell and selectively inhibit degradative pathway. It includes peptide aldehydes, such as Cbz-leu-leu-leucinal (MG132), Cbz-leu-leu-norvalinal (MG115) and acetyl-leu-leu-norleucinal (ALLN). These are substrate analogues and potent transition-state inhibitors of chymotrypsin like activity of proteasome machinery. The peptide aldehydes are also known to inhibit certain lysosomal cysteine proteases and the calpains hence MG132 may not be exclusive inhibitor of proteasomal pathway.
== Personal life == Born in September 1964, Phillips was raised in Golden, Colorado, where he lived with his father Bill (often referred to as BP), mother Suzanne, sister Shelly and brother Shawn. His father, William Phillips Sr., worked for the Coors Brewing Company while taking law classes at night. He reached the level of corporate analyst at Coors, then quit to open his own law practice. BP later worked for Phillips at EAS, along with other family members. Phillips started bodybuilding in 1982, then moved to Southern California to train at Gold's Gym Venice Beach (known as the Mecca of bodybuilding) in 1983, remaining until 1986, a period during which Phillips admits to steroid use, at different times cycling on Deca Durabolin, Andriol, Sustanon, and other drugs that helped him grow from 185 lbs. to 215 lbs. After not succeeding as a bodybuilder, the 21-year-old Phillips moved back to Colorado where he took classes at the University of Colorado at Denver, specifically the study of exercise physiology and sports nutrition. He then began his publishing career. On June 25, 2021, Phillips was admitted to St. Anthony Hospital in Lakewood and attached to a ventilator after a COVID-19 infection, where he spent 47 days intubated recovering from being in a medically induced coma. He lost 70 pounds. When Phillips was admitted to the hospital he already had pneumonia. ″I did not get vaccinated because I made a mistake,″ Phillips said after recuperating in August 2021. ″I thought since I had COVID in January 2020, I was immune to it."
Sources: en.wikipedia.org
As clean energy from wind, solar or hydro storage replaces pollution from gas, oil and coal, EU law has standards for generation and distribution networks. First, in generation, the Renewable Energy Directive 2018 still enables biomass and biofuel to count toward "renewable" energy statistics based on the argument that trees or plants absorb greenhouse gases when they grow, even though biomass burning (usually in ex-coal plants) releases more greenhouse gases than coal, biomass transport is not clean, forests take decades to replenish, and smoke damages human health. Second, the EU does not yet have a feed-in tariff system, requiring energy grids and retailers to pay a fair price to households or businesses with solar or wind generation, however in PreussenElektra AG v Schleswag AG the Court of Justice held that member states could fix any price they chose, so that energy companies would have to reimburse producers for the energy they received. A company now owned by E.ON claimed the feed-in tariff was state aid under TFEU article 107, and should have to pass rules for exemption, as a way to hinder renewable energy funding. The Court rejected this, because although the policy might have 'negative repercussions' for big energy companies it 'cannot be regarded' as giving to small producers 'a particular advantage at the expense of the state'.
== Rationale == Gum grafting, also known as a gingival graft or periodontal plastic surgery, is a surgical procedure to reverse gum recession. Gum recession exposes the roots of teeth, which can lead to sensitivity and put teeth at a higher risk of damage or disease due to the loosening of their attachment within the gums and bones of the jaw. Should gum recession continue, bone and keratinized tissue will be at greater risk of being damaged and permanently lost around the teeth. The aim of a gum graft is to extend keratinized tissue of the gums to cover tooth roots, which restores their firm placement within the jaw and prevents further damage.
Polysubstance use or poly drug use refers to the use of combined psychoactive substances. Polysubstance use may be used for entheogenic, recreational, or off-label indications, with both legal and illegal substances. In many cases one drug is used as a base or primary drug, with additional drugs to leaven or compensate for the side effects, or tolerance, of the primary drug and make the experience more enjoyable with drug synergy effects, or to supplement for primary drug when supply is low.
=== Zachery treatment === A proprietary process was created by electrical engineer and turquoise dealer James E. Zachery in the 1980s to improve the stability of medium to high-grade turquoise. The process can be applied in several ways: either through deep penetration on rough turquoise to decrease porosity, by shallow treatment of finished turquoise to enhance color, or both. The treatment can enhance color and improve the turquoise's ability to take a polish. Such treated turquoise can be distinguished in some cases from natural turquoise, without destruction, by energy-dispersive X-ray spectroscopy, which can detect its elevated potassium levels. In some instances, such as with already high-quality, low-porosity turquoise that is treated only for porosity, the treatment is undetectable.
=== Serum albumin purification === Affinity purification of albumin and macroglobulin contamination is helpful in removing excess albumin and α2-macroglobulin contamination, when performing mass spectrometry. In affinity purification of serum albumin, the stationary used for collecting or attracting serum proteins can be Cibacron Blue-Sepharose. Then the serum proteins can be eluted from the adsorbent with a buffer containing thiocyanate (SCN−).
Sources: en.wikipedia.org
Many complexes are known with cyclopropenium ligands. Examples include [M(C3Ph3)(PPh3)2]+ (M = Ni, Pd, Pt) and Co(C3Ph3)(CO)3. Such compounds are prepared by reaction of cyclopropenium salts with low valent metal complexes.
Culver's was still a small, local chain in 1993, with only 14 restaurants across southern Wisconsin. Their first restaurants outside Wisconsin opened in Buffalo, Minnesota in September 1995, Roscoe, Illinois in December 1995, and Dubuque, Iowa in November 1997.
== Homicides == Thailand ranked 30 of 216 countries for its number of homicides (2,387) in 2015. Other ASEAN nations ranked: Philippines, 14 (9,756 homicides); Vietnam, 39 (1,358); Myanmar, 41 (1,304); Indonesia, 42 (1,277); Malaysia, 74 (540); Laos, 79 (467); Cambodia, 100 (268); Singapore, 175 (14); Brunei, 197 (2). Among ASEAN nations, the Philippines had the highest rate of homicides per 100,000 population (9.84), followed by Laos (6.87), and Thailand (3.51). Singapore had the lowest homicide rate in ASEAN, with just 0.25 murders per 100,000 population.
=== Later research and leadership === Lawrence continued to direct her laboratory for more than fifty years, and it developed a reputation for reliability among investigators. She worked closely with the Board of Medical Examiners in Portland. Beyond her laboratory work, Lawrence was active in professional and civic organizations. Lawrence became a fellow with the newly formed American Society of Clinical Pathologists in 1927. The goal of the organization was to advance the field of clinical pathology and to ensure it was on equal ground with other specialized areas of medicine. She was a member of the Medical Club of Portland where she worked with other notable women physicians such as Mae Cardwell, Jessie Fern McGavin, and Amelia Zeigler. Lawrence also supported the local chapter of the Philanthropic Educational Organization (P.E.O.) Sisterhood, which was an international organization that worked to provide educational opportunities for women. Through these affiliations she encouraged women to enter medicine and advocated for equal educational opportunities. In 1963, Boston University’s General Alumni Association awarded her its Distinguished Alumni Award. She retired in 1967.
=== Spectroscopy === In quantum mechanics, the energy levels of electrons in atoms depend on the reduced mass of the system of electron and nucleus. For a hydrogen atom, the role of reduced mass is most simply seen in the Bohr model of the atom, where the reduced mass appears in a simple calculation of the Rydberg constant and Rydberg equation, but the reduced mass also appears in the Schrödinger equation, and the Dirac equation for calculating atomic energy levels. The reduced mass of the system in these equations is close to the mass of a single electron, but differs from it by a small amount about equal to the ratio of mass of the electron to the nucleus. For 1H, this amount is about 1837/1836, or 1.000545, and for 2H it is even smaller: 3671/3670, or 1.000272. The energies of electronic spectra lines for 2H and 1H therefore differ by the ratio of these two numbers, which is also very close to 1.000272. The wavelengths of all deuterium spectroscopic lines are shorter than the corresponding lines of light hydrogen, by 0.0272%. In astronomical observation, this corresponds to a blue Doppler shift of 0.0272% of the speed of light, or 81.6 km/s. The differences are much more pronounced in vibrational spectroscopy such as infrared spectroscopy and Raman spectroscopy, and in rotational spectra such as microwave spectroscopy because the reduced mass of the deuterium is markedly higher than that of protium. In nuclear magnetic resonance spectroscopy, deuterium has a very different NMR frequency (e.g. 61 MHz when protium is at 400 MHz) and is much less sensitive.
Sources: en.wikipedia.org
Filtering removes particulate matter that can block columns or scatter light. A 0.22 micrometre membrane is typical, and the filter material should be checked for peptide adsorption.
Peptides can bind to glass and plastic, so a fraction of the material leaves the solution. The effect is proportionally larger in dilute samples and can bias quantitative results.
Reverse-phase high-performance liquid chromatography is the most widely reported approach. Purity figures should always be quoted together with the wavelength, gradient, and integration parameters used.
Ice formation concentrates solutes and can mechanically stress the peptide or damage the delivery device. Thawing afterwards may leave aggregates that are not visible to the eye. Refrigeration keeps the solution above its freezing point while slowing chemical degradation.